Lazard steps back from Sanofi and Aventis

Lazard's close relationship with Pfizer, the world's biggest drug company, has cost it an advisory role in Sanofi's €47.8bn ($59.6bn) hostile bid for Aventis.

The Paris office of Lazard has worked for both Sanofi and Aventis in the past and was keen to have a role in the deal, according to banking sources.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump